» Articles » PMID: 29720545

Multifocal Demyelinating Motor Neuropathy and Hamartoma Syndrome Associated with a De Novo Mutation

Abstract

Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases.

Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts.

Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice.

Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway.

Citing Articles

Recessive Variants in PIGG Cause a Motor Neuropathy with Variable Conduction Block, Childhood Tremor, and Febrile Seizures: Expanding the Phenotype.

Record C, OConnor A, Verbeek N, van Rheenen W, Zamba Papanicolaou E, Peric S Ann Neurol. 2024; 97(2):388-396.

PMID: 39444079 PMC: 11740278. DOI: 10.1002/ana.27113.


Protein signature of human skin fibroblasts allows the study of the molecular etiology of rare neurological diseases.

Hentschel A, Czech A, Munchberg U, Freier E, Schara-Schmidt U, Sickmann A Orphanet J Rare Dis. 2021; 16(1):73.

PMID: 33563298 PMC: 7874489. DOI: 10.1186/s13023-020-01669-1.


Acidic fibroblast growth factor attenuates type 2 diabetes-induced demyelination via suppressing oxidative stress damage.

Li R, Wang B, Wu C, Li D, Wu Y, Ye L Cell Death Dis. 2021; 12(1):107.

PMID: 33479232 PMC: 7819983. DOI: 10.1038/s41419-021-03407-2.


Abnormal Head Size in Children and Adolescents with Congenital Nervous System Disorders or Neurological Syndromes with One or More Neurodysfunction Visible since Infancy.

Perenc L, Guzik A, Podgorska-Bednarz J, Druzbicki M J Clin Med. 2020; 9(11).

PMID: 33233862 PMC: 7699836. DOI: 10.3390/jcm9113739.

References
1.
Malek M, Kielkowska A, Chessa T, Anderson K, Barneda D, Pir P . PTEN Regulates PI(3,4)P Signaling Downstream of Class I PI3K. Mol Cell. 2017; 68(3):566-580.e10. PMC: 5678281. DOI: 10.1016/j.molcel.2017.09.024. View

2.
Rodriguez-Escudero I, Oliver M, Andres-Pons A, Molina M, Cid V, Pulido R . A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum Mol Genet. 2011; 20(21):4132-42. DOI: 10.1093/hmg/ddr337. View

3.
Bansagi B, Griffin H, Whittaker R, Antoniadi T, Evangelista T, Miller J . Genetic heterogeneity of motor neuropathies. Neurology. 2017; 88(13):1226-1234. PMC: 5373778. DOI: 10.1212/WNL.0000000000003772. View

4.
Ansong E, Ying Q, Ekoue D, Deaton R, Hall A, Kajdacsy-Balla A . Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer. PLoS One. 2015; 10(5):e0127295. PMC: 4436248. DOI: 10.1371/journal.pone.0127295. View

5.
Sarker D, Ang J, Baird R, Kristeleit R, Shah K, Moreno V . First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014; 21(1):77-86. PMC: 4287394. DOI: 10.1158/1078-0432.CCR-14-0947. View